EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of epigenetic chemical probes: expanding targeting modalities and disease understanding

Philip Barbulescu, Cheryl H Arrowsmith iD, Dalia Barsyte-Lovejoy iD

Essays in Biochemistry · 18.11.2026

DOI: 10.1042/ebc20260009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Essays in Biochemistry, online erschienen am 18.11.2026. Verfasst von Philip Barbulescu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Structural Genomics Consortium, Toronto, ON, Canada. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR | Institute of Cancer Research (IC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small-molecule chemical modulators (chemical probes) targeting epigenetic regulators are essential tools for research by enabling precise temporal control over chromatin dynamics. Over the past two decades, large international efforts have produced hundreds of validated and openly accessible chemical probes. While the field was initially driven by occupancy-based catalytic inhibitors, there has been a recent shift toward context-dependent target engagement and induced proximity strategies. By repurposing established chemical ligands, next-generation heterobifunctional modalities (e.g., PROTACs and RIPTACs) can drive targeted protein degradation or disrupt multi-protein complexes to achieve deeper functional effects. In the present review, we discuss the evolution of epigenetic chemical probes, the emergence of induced proximity strategies, and the importance of recognizing that different targeting modalities for a given protein may yield distinct biological outcomes. Collectively, the history of epigenetic probes provides a foundation for Target 2035, an international initiative led by the Structural Genomics Consortium aimed at developing pharmacological modulators across the human proteome.

Schlagwörter

Stichwörter der Autor:innen

PROTACchemical biologychemical probesepigenetics

Autor:innen und Institutionen

  • Structural Genomics Consortium, Toronto, ON, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
  • Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Cheryl H Arrowsmith, Dalia Barsyte-Lovejoy

Förderung

  • CIHR | Institute of Cancer Research (IC)

Zitieren

APA

Barbulescu, P., Arrowsmith, C. H., & Barsyte-Lovejoy, D. (2026). The impact of epigenetic chemical probes: expanding targeting modalities and disease understanding. Essays in Biochemistry. https://doi.org/10.1042/ebc20260009

Vancouver

Barbulescu P, Arrowsmith CH, Barsyte-Lovejoy D. The impact of epigenetic chemical probes: expanding targeting modalities and disease understanding. Essays in Biochemistry. 2026. doi:10.1042/ebc20260009

BibTeX
@article{Barbulescu2026,
  author = {Barbulescu, Philip and Arrowsmith, Cheryl H and Barsyte-Lovejoy, Dalia},
  title = {The impact of epigenetic chemical probes: expanding targeting modalities and disease understanding},
  journal = {Essays in Biochemistry},
  year = {2026},
  doi = {10.1042/ebc20260009}
}
Kostenlos starten →